Renal considerations in cardiovascular drug therapy.
The increasing number of patients with both cardiac and renal disease makes it important for the clinician to bear in mind the effect of both renal failure and peritoneal or hemodialysis on the handling of drugs. Guidelines are available for specific medications; however, they must be used in the light of the patient's individual response and metabolism.
Feinfeld
D A
DA
Albert Einstein College of Medicine, Bronx, New York.
Frishman
W H
WH
D058186:Acute Kidney Injury; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D002317:Cardiovascular Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000008:administration & dosage; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic; D010530:Peritoneal Dialysis; D006435:Renal Dialysis
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D004071:Digitalis Glycosides